Intra-articular injection of an extended-release flavopiridol formulation represents a potential alternative to other intra-articular medications for treating equine joint disease.

The researchers examined the effects of a potential new treatment for equine joint disease. They did this by injecting a solution that includes the drug flavopiridol, encapsulated within small particles, into the joints of healthy horses. The drug was released over time, and the research showed that it remained in the joint area for up to four weeks with minimal absorption into the bloodstream, which suggests it could offer a sustained, localised treatment for joint issues in horses.

Objective and Methodology

• The study aimed to understand the behavior, effectiveness, and possible side effects of a new application of the drug, flavopiridol, in treating equine joint diseases.
• Flavopiridol, known for its anti-inflammatory and analgesic properties, was presented in an extended-release formulation using PLGA (poly lactic-co-glycolic acid) microparticles.
• A total of four healthy horses were used for this study, with a saline solution containing flavopiridol introduced into one joint, and a control saline solution without flavopiridol injected into the opposite joint.
• The research was conducted in two phases (each lasting six weeks), during which samples of synovial fluid and blood were collected at different points for analysis.
• The researchers measured drug concentration, protein levels, and cell count in synovial fluid to monitor the presence and potential effects of the drug.
• Comprehensive biochemistry tests and observations for signs of lameness were also performed at each time point to assess if any systemic side effects occurred.

Findings and Conclusion

• The results showed that detectable levels of flavopiridol remained in the synovial fluid up to four weeks post-injection.
• The concentration of the drug gradually decreased over the period, becoming almost undetectable by weeks five and six.
• No systemic absorption of the drug was found, meaning it didn’t enter the horses’ general bloodstream – a positive outcome considering the intention is for the drug to treat local joint issues.
• Importantly, no adverse effects or signs of lameness were observed in any of the horses during the study.
• The findings suggest that flavopiridol, when used in an extended-release PLGA microparticle formulation, can provide a localized, sustained presence in joint areas, making it a potential alternative for treating equine joint diseases.